These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12172398)

  • 1. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil.
    Bossé Y; Pascot A; Dumont M; Brochu M; Prud'homme D; Bergeron J; Després JP; Vohl MC
    Genet Med; 2002; 4(4):311-5. PubMed ID: 12172398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
    Tai ES; Collins D; Robins SJ; O'Connor JJ; Bloomfield HE; Ordovas JM; Schaefer EJ; Brousseau ME
    Atherosclerosis; 2006 Jul; 187(1):153-60. PubMed ID: 16221474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
    Flavell DM; Jamshidi Y; Hawe E; Pineda Torra I; Taskinen MR; Frick MH; Nieminen MS; Kesäniemi YA; Pasternack A; Staels B; Miller G; Humphries SE; Talmud PJ; Syvänne M
    Circulation; 2002 Mar; 105(12):1440-5. PubMed ID: 11914252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.
    Robitaille J; Brouillette C; Houde A; Lemieux S; Pérusse L; Tchernof A; Gaudet D; Vohl MC
    J Hum Genet; 2004; 49(9):482-489. PubMed ID: 15309680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study.
    Tai ES; Demissie S; Cupples LA; Corella D; Wilson PW; Schaefer EJ; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):805-10. PubMed ID: 12006394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil.
    Bossé Y; Vohl MC; Dumont M; Brochu M; Bergeron J; Després JP; Prud'homme D
    Clin Genet; 2002 Jul; 62(1):45-52. PubMed ID: 12123487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population.
    González Sánchez JL; Serrano Ríos M; Fernández Perez C; Laakso M; Martínez Larrad MT
    Eur J Endocrinol; 2002 Oct; 147(4):495-501. PubMed ID: 12370112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
    Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
    Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
    Doggrell SA
    Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARalpha L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity.
    Rudkowska I; Caron-Dorval D; Verreault M; Couture P; Deshaies Y; Barbier O; Vohl MC
    Mol Nutr Food Res; 2010 Apr; 54(4):543-50. PubMed ID: 19937854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
    Gouni-Berthold I; Giannakidou E; Faust M; Berthold HK; Krone W
    Atherosclerosis; 2005 Dec; 183(2):336-41. PubMed ID: 16285997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
    Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ
    J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men.
    Skogsberg J; McMahon AD; Karpe F; Hamsten A; Packard CJ; Ehrenborg E;
    J Intern Med; 2003 Dec; 254(6):597-604. PubMed ID: 14641801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM
    Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
    JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
    Dumont M; Mauriège P; Bergeron J; Després JP; Prud'homme D
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1136-43. PubMed ID: 11477498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease.
    Wang XL; Oosterhof J; Duarte N
    Cardiovasc Res; 1999 Dec; 44(3):588-94. PubMed ID: 10690291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus.
    Evans D; Aberle J; Wendt D; Wolf A; Beisiegel U; Mann WA
    J Mol Med (Berl); 2001 May; 79(4):198-204. PubMed ID: 11409711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
    Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.